KALA · KALA BIO, Inc.
$0.66
-0.01 (-0.79%)
At close · Jul 29
Market Cap
$12.27M
Shares
18.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.66
Open$0.65
Day$0.62–0.69
52W$0.59–1,030.00
Avg vol 30d189K
Short int257K · 1.4% float · 1.2d
Short vol39%
Last earningsAug 8, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bearish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.2 · elevated
Equity put/call 0.71
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−97%
below
Price vs 50-day avg
−67%
below
RSI (14)
24
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−68%
trailing
6-month return
−97%
trailing
YTD return
−98%
this year
Relative strength
−105%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $20 — 200d above 50d
Institutional flow
Distributing
3 of 27 funds reported for Jun 30 · net -400 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.38% of float · ▲ +17.4% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — mid 3-yr range
Squeeze score
37
low risk · 0–100
Fundamentals
EPS growth
+67%
Y/Y
Free cash flow
$-33.3M
Balance sheet
$22.9M
net debt
Quant / Vol
risk profile
Volatility
165%
annualized · 1-yr
Max drawdown
−100%
past year
ATR
33.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−97%
Bearish
Price vs 50-day avg
−67%
Bearish
RSI (14)
24
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $20 — 200d above 50d
Institutional flow
Distributing
3 of 27 funds reported for Jun 30 · net -400 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.38% of float · ▲ +17.4% MoM · 1.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
27 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 0%
52-wk high $1,030
vs 200-day avg -97%
vs 50-day avg -67%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KALA
this stock
KALA BIO, Inc.
|
$12.27M | -97.6% | — | — | 1.4% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +8.8% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$124.46B | +8.2% | +46.2% | 29.1 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.88B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +3.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KALA | -9.9% | -68.4% | -97.2% | -61.8% | -97.6% |
| SPY | -1.0% | 0.0% | +7.4% | -0.8% | +8.6% |
| vs SPY | -8.9% | -68.4% | -104.6% | -61.1% | -106.3% |